• Top Picks
    • PosterPerspectives: NSCLC Posters and Abstracts from Chicago
    • The Patient with Multiple Myeloma
    • Melanoma Antigen Challenge <br>Tumor-derived antigens set the immune system in motion against melanoma
    • MPN Central

Select a Topic

  • FILTER BY:
Immunotherapy Updates 2015: FOCUS on NSCLC
CME

Immunotherapy Updates 2015: FOCUS on NSCLC

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Expiration Date: 7/28/2016
Credit Type(s): CME | Credit: 0.75

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers. Approximately 70% of patients…

go to activity»
Tailored Therapies for Myelodysplastic Syndromes
CME

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Expiration Date: 6/29/2016
Credit Type(s): CME | Credit: 1

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical manifestations. The main clinical complication in MDS is…

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Chronic Lymphocytic Leukemia

No commercial support for this activity.

Expiration Date: 6/15/2016
Credit Type(s): CME | Credit: 0.25

This CME activity will focus on the diagnosis and management of patients with chronic lymphocytic leukemia….

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Multiple Myeloma

No commercial support for this activity.

Expiration Date: 7/15/2016
Credit Type(s): CME | Credit: 0.25

This CME activity will focus on the diagnosis and management of patients with multiple myeloma….

go to activity»
M608ActivityImage
CME

PosterPerspectives: NSCLC Posters and Abstracts from Chicago

This activity is supported by an independent educational grant from AstraZeneca.
Supported by an educational grant from Genentech.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

June 30, 2015

The following abstracts and posters were curated from all the posters presented at the 2015 American Society of Clinical Oncology meeting. The posters look at a several…

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Melanoma

No commercial support for this activity.

Expiration Date: 5/15/2016
Credit Type(s): CME | Credit: 0.25

This CME activity will focus on the diagnosis and management of patients with melanoma….

go to activity»
Immunotherapy Updates 2015: FOCUS on NSCLC
CME

Immunotherapy Updates 2015: FOCUS on NSCLC

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Expiration Date: 7/28/2016
Credit Type(s): CME | Credit: 0.75

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers. Approximately 70% of patients…

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Multiple Myeloma

No commercial support for this activity.

Expiration Date: 7/15/2016
Credit Type(s): CME | Credit: 0.25

This CME activity will focus on the diagnosis and management of patients with multiple myeloma….

go to activity»
Tailored Therapies for Myelodysplastic Syndromes
CME

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Expiration Date: 6/29/2016
Credit Type(s): CME | Credit: 1

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical manifestations. The main clinical complication in MDS is…

go to activity»
M608ActivityImage
CME

PosterPerspectives: NSCLC Posters and Abstracts from Chicago

This activity is supported by an independent educational grant from AstraZeneca.
Supported by an educational grant from Genentech.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

June 30, 2015

The following abstracts and posters were curated from all the posters presented at the 2015 American Society of Clinical Oncology meeting. The posters look at a several…

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Chronic Lymphocytic Leukemia

No commercial support for this activity.

Expiration Date: 6/15/2016
Credit Type(s): CME | Credit: 0.25

This CME activity will focus on the diagnosis and management of patients with chronic lymphocytic leukemia….

go to activity»
Hematology Oncology Case Consults
CME

The Patient with Melanoma

No commercial support for this activity.

Expiration Date: 5/15/2016
Credit Type(s): CME | Credit: 0.25

This CME activity will focus on the diagnosis and management of patients with melanoma….

go to activity»
MPN Central

MPN Central

Supported by Incyte Corporation through an independent third-party educational grant.

April 24, 2015

MPN Central is an essential resource center dedicated to helping physicians effectively and efficiently communicate MPN diagnosis and treatment options to their…

go to activity»
Hematology Oncology Case Consults
CME

Diagnosis and Management of Hemophilia

No commercial support for this activity.

Expiration Date: 4/15/2016
Credit Type(s): CME | Credit: 0.25

This CME activity will focus on the diagnosis and management of the patient with hemophilia supplemented with a case presentation….

go to activity»
Melanoma Antigen Challenge

Melanoma Antigen Challenge
Tumor-derived antigens set the immune system in motion against melanoma

This activity is sponsored as an educational service by Amgen.

January 14, 2015

Take the Melanoma Antigen Challenge to learn about melanoma and factors that can trigger an immune response against it….

go to activity»
Progression-free Survival Data Updated Overall Survival Analysis for HR+mBC Treatment

Watch this brief video about prolonged PFS and updated OS data analysis for HR+ mBC Treatment….

go to activity»
Melanoma: Updates on risks and treatment options

Melanoma is one of the most dangerous forms of skin cancer, causing 75% of deaths associated with skin cancer. There are approximately 48,000 deaths associated with…

go to activity»
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia
CME

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

Expiration Date: 8/15/2015
Credit Type(s): CME | Credit: 1.5

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances have shown that 70% of cases are the result of…

go to activity»
Activity cover
CME

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Expiration Date: 8/15/2015
Credit Type(s): CME | Credit: 1

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in development, with the hope of dramatically improving…

go to activity»
Hot melanoma

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in development, with the hope of dramatically improving…

go to activity»
Applying Imaging, Biomarkers, and Immunotherapy in the Management of NSCLC
CME

Applying Imaging, Biomarkers, and Immunotherapy in the Management of NSCLC

This activity is supported by an educational grant from Genentech, Inc.

Expiration Date: 8/6/2015
Credit Type(s): CME | Credit: 1

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, but the numerous subtypes make this disease challenging to accurately diagnose and manage…

go to activity»
MPN Updates

MPN Updates

This electronic newsletter is sponsored by Incyte Corp. through a third-party independent grant.

January 8, 2014

As the standards of care for patients with myeloproliferative neoplasms (MPNs) continue to evolve, physicians must stay informed on current research and treatment…

go to activity»
PD-1 Antibodies
CME

PD-1 Antibodies

This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.

Expiration Date: 11/30/2015
Credit Type(s): CME | Credit: 0.25

This activity will review data on the efficacy, safety, and response patterns observed with PD-1 in patients with advanced melanoma….

go to activity»
Building on the Success of CTLA-4 Blockade in Melanoma Immunotherapy
CME

Building on the Success of CTLA-4 Blockade in Melanoma Immunotherapy

This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.

Expiration Date: 11/30/2015
Credit Type(s): CME | Credit: 0.25

This activity will review data on the efficacy, safety, and response patterns observed with ipilimumab in patients with advanced melanoma….

go to activity»
Enhancing Patient and Health Care Team Communications: Paving the way for success

Enhancing Patient and Health Care Team Communications: Paving the way for success

This HemOnc Today supplement is produced by SLACK Incorporated and sponsored as an educational service by Cephalon, a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.

December 1, 2011

Effective communication between health care providers and patients diagnosed with cancer is an essential part of the treatment process. Communicating effectively ensures…

go to activity»